Published online before print March 1, 2004, doi: 10.1161/01.CIR.0000118462.22970.BE
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:1299-1306.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Unique, Highly Proliferative Growth Phenotype Expressed by Embryonic and Neointimal Smooth Muscle Cells Is Driven by Constitutive Akt, mTOR, and p70S6K Signaling and Is Actively Repressed by PTEN
From the Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colo.
Correspondence to Dr Mary C.M. Weiser-Evans, Department of Pediatrics, University of Colorado Health Sciences Center, Box B131, 4200 E Ninth Ave, Denver, CO 80262. E-mail Mary.Weiser{at}UCHSC.edu
Received March 5, 2003; de novo received August 11, 2003; revision received October 31, 2003; accepted November 17, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionResultsDiscussionReferences |
|---|
Background— At distinct times during embryonic development and after vascular injury, smooth muscle cells (SMCs) exhibit a highly proliferative, serum-independent growth phenotype. The aim of the present study was to evaluate the functional role of S6 ribosomal protein (S6RP) and upstream positive and negative regulators in the control of SMC serum-independent growth.
Methods and Results— We previously reported increased expression of S6RP mRNA was associated with this unique growth phenotype. Using immunohistochemistry and Western blot analysis, we report high levels of total and phospho-S6RP and increased levels of Akt and p70S6K phosphorylation, upstream positive regulators of S6RP, in rat embryonic aortas and adult balloon-injured carotid arteries compared with quiescent adult aortas and uninjured carotid arteries. Western blot analysis demonstrated that cultured embryonic and neointimal SMCs that exhibited serum-independent growth capabilities expressed high levels of S6RP and constitutively active Akt, mTOR, and p70S6K. Pharmacological and molecular inhibition of phosphatidylinositol 3-kinase (PI3K) signaling pathways, using PI3K inhibitors, rapamycin, or dominant-negative Akt adenovirus, suppressed embryonic and neointimal SMC serum-independent growth. Finally, decreased activity of PTEN, an endogenous negative regulator of PI3K signaling, was associated with high in vivo SMC growth rates, and morpholino-mediated loss of endogenous PTEN induced a serum-independent growth phenotype in cultured serum-dependent SMCs.
Conclusions— The possibility exists that cells that exhibit a distinct embryonic-like growth phenotype different from traditional SMCs are major contributors to intimal thickening. Growth of SMCs that exhibit this phenotype is dependent on constitutive Akt and mTOR/p70S6K signaling and is actively inhibited through the timed acquisition of the endogenously produced growth suppressor PTEN.
Key Words: cells • restenosis • muscle, smooth • aorta • carotid arteries
|
Introduction |
|---|
|
TopAbstractIntroductionResultsDiscussionReferences |
|---|
Vascular smooth muscle cell (SMC) proliferation plays a prominent role in normal vessel development and in many vascular pathologies, including restenosis after angioplasty and stent placement and atherosclerosis. The mechanisms that regulate SMC proliferation during vascular development and in response to vascular injury in the adult blood vessel, however, have yet to be fully elucidated. During development, aortic SMCs undergo a phase of rapid proliferation, during which the vessel wall acquires its complement of SMCs.1 Replication rates decrease as the animal matures, with SMCs eventually reaching a quiescent state in the adult animal.1,2 However, after injury to an adult artery, transient increases in SMC replication to levels similar to those exhibited during embryonic life are observed in the neointima.2,3
Corresponding to high in vivo growth rates, SMCs cultured from embryonic aortas exhibit a distinct growth phenotype characterized by rapid serum-stimulated growth and the ability to replicate in a mitogen- or serum-independent manner.1 This growth phenotype is lost by fetal life, with fetal-, neonatal-, and adult-derived SMCs exhibiting slower growth rates in response to serum stimulation and loss of serum-independent growth. SMCs derived at specific times from injured adult vessels, however, exhibit a similar growth phenotype at a time correlating to peak in vivo neointimal SMC growth.3 Thus, SMCs are capable of transiently reexpressing an embryonic-like, serum-independent growth phenotype. Additionally, we3 reported adult-derived serum-dependent SMCs possess a "suppressor activity" that continually and actively controls SMC replication by extinguishing serum-independent growth potential. This suppressor activity is first detected in the fetal period of development when the potential for SMC serum-independent growth is no longer detected and is only lost or inactivated after vascular injury corresponding to reexpression of a serum-independent growth phenotype. These observations are consistent with the possibility that mechanisms that contribute to vascular injury repair are a partial reiteration of early vascular developmental processes.
Our previous work used subtractive hybridization analysis to identify genes associated with both high rates of in vivo SMC growth and in vitro serum-independent growth.4 We identified S6 ribosomal protein (S6RP) as being one of these proteins. The aim of the present study was to further evaluate the functional role of S6RP in SMC serum-independent growth and to identify upstream positive and negative regulators involved in the control of SMC serum-independent growth. We report here constitutively active phosphatidylinositol 3-kinase (PI3K)/Akt-induced signaling molecules are important contributors to the highly proliferative, serum-independent SMC phenotype, and PTEN, an endogenous inhibitor of PI3K signaling, negatively regulates serum-independent growth potential.
|
Results |
|---|
|
TopAbstractIntroductionResultsDiscussionReferences |
|---|
High Levels of Total S6RP, Phospho-Akt, Phospho-p70S6K, and Phospho-S6RP Correlate to High In Vivo SMC Growth Rates
Our previous data showed S6RP mRNA was upregulated in embryonic-derived, serum-independent SMCs compared with adult-derived, serum-dependent SMCs.4 Using immunohistochemistry on tissue sections, we found higher total S6RP in embryonic aortas and in the neointima of 7-day postinjury carotid arteries compared with adult aortic and sham-injured carotid arterial tissues (Figure 1A). S6RP phosphorylation increases cell cycle progression.5 In addition to an increase in total protein, we also found increased levels of phospho-S6RP in embryonic and injured arterial sections compared with adult aortic and sham-injured carotid artery sections (Figure 1A). Western blot analysis of vessel protein expressions confirmed the immunohistochemistry data (Figure 1B).
|
S6RP has a known role in translation initiation and cell cycle progression and is a downstream effector of PI3K/Akt/p70S6K signaling pathways.5,6 We therefore hypothesized increased activity of this signaling pathway in embryonic and postinjury vessels may be associated with high growth rates. Using Western blot analysis on arterial tissues, we found increased levels of Akt and p70S6K phosphorylation in embryonic and postinjury vessels compared with adult aortic and sham-injured carotid artery vessels (Figure 1B).
Cultured, Serum-Independent Embryonic and Neointimal SMCs Express High Levels of S6RP and Constitutively Active Akt, mTOR, and p70S6K
PI3K/Akt and mTOR/p70S6K signaling plays a pivotal role in essential cellular functions such as cell growth and survival.5–7 PI3K controls translation initiation and cell cycle progression through the activation of its downstream effector, Akt/PKB. Akt can signal to p70S6K via mTOR activation, which results in phosphorylation of S6RP and increased translation of cell cycle–associated genes, such as cyclins and cyclin-dependent kinases.6–8 We therefore next determined whether embryonic aortic and carotid artery neointimal SMCs, which exhibit high rates of DNA synthesis when cultured under serum-free conditions, exhibit constitutively active Akt-mediated signaling, thus contributing to serum-independent growth. Using Western blot analysis, we found increased levels of total S6RP and phospho-S6RP and constitutively phosphorylated Akt, mTOR, and p70S6K in serum-deprived but growing embryonic and neointimal SMCs (Figure 2). In contrast, growth-arrested adult SMCs showed significantly decreased total S6RP and decreased phosphorylation of all signaling molecules, which suggests that rapid and serum-independent growth of embryonic and neointimal SMCs is driven, at least in part, by increased activity of Akt- and mTOR/p70S6K-dependent signaling.
|
Pharmacological and Molecular Inhibition of PI3K Signaling Blocks Embryonic and Neointimal SMC Serum-Independent Growth
To examine the possibility that PI3K-mediated signaling plays a functional role in conferring this highly proliferative growth phenotype, we used a systematic pharmacological and molecular approach to inhibit several levels of this pathway. The effects of rapamycin, a specific mTOR inhibitor, an adenoviral construct expressing an inactive form of Akt (dnAkt), and the PI3K inhibitors LY294002 and wortmannin on SMC serum-independent growth were tested. Control (untreated), vehicle-treated, and green-fluorescing protein-transduced embryonic and neointimal SMCs showed high rates of DNA synthesis under serum-deprived conditions, whereas adult SMCs were effectively growth arrested under serum-deprived conditions (Figure 3A). Rapamycin decreased embryonic and neointimal SMC DNA synthesis by 72% and 68%, respectively. Likewise, embryonic and neointimal SMCs incubated with pAd-dnAkt or treated with LY294002 or wortmannin showed decreased rates of DNA synthesis under serum-deprived conditions (pAd-dnAkt 58% and 61%, respectively; LY294002 80% and 78%, respectively; Wortmannin 58% and 56%, respectively). Inhibitors and dnAkt virus had little effect on the already low DNA synthesis of quiescent adult SMCs (Figure 3A). Western blot analysis confirmed LY-294002, Wortmannin, and pAd-dnAkt inhibited phosphorylation of Akt, mTOR, p70S6K, and S6RP, whereas rapamycin more specifically inhibited phosphorylation of mTOR, p70S6K, and S6RP (Figure 3B). Inhibitors/dominant-negative virus had no effect on the rate of apoptosis (P.M. Mourani et al, unpublished data).
|
We also tested whether activation of the Akt pathway, sufficient to drive activation of all downstream targets investigated here, can induce a serum-independent growth phenotype. Serum-independent growth and Akt, mTOR, p70S6K, and S6RP phosphorylation of adult SMCs were induced when cells were transduced with an adenoviral vector expressing constitutively active Akt (MyrAkt; Figure 3A). Transduction of MyrAkt in embryonic and neointimal SMCs did not significantly enhance the proliferative responses or phosphorylation levels of downstream targets, which suggests that the contribution of Akt activity in these cells is at a maximal state. Collectively, these results suggest that Akt-dependent, mTOR/p70S6K-sensitive pathways are essential regulators of SMC serum-independent growth.
Decreased Activity of PTEN Is Associated With High In Vivo SMC Growth Rates, and Loss of PTEN Induces a Serum-Independent Growth Phenotype In Vitro
The above data strongly suggest constitutive PI3K/Akt-induced signaling mediates SMC serum-independent growth, at least in part. Control of this pathway, as observed in adult-derived SMCs, could occur via loss of upstream positive regulators or via the acquisition of negative regulators. Our previous work suggested serum-independent growth is actively controlled through the timed acquisition of a suppressor activity.3 We therefore focused our studies on the potential role of PTEN, an endogenous negative regulator of PI3K signaling, in controlling embryonic and neointimal SMC serum-independent growth. PTEN, a dual-specificity lipid and protein phosphatase, promotes cell cycle arrest by downregulating PI3K/Akt signaling9–12 and is inactive when phosphorylated.13,14 Except for a single report,15 little is known of the physiological role of PTEN in vascular SMCs. Western blot analysis showed equal amounts of total PTEN protein expressed by embryonic and adult aortas and sham-injured and 7-day-injured carotid arteries (Figure 4). In contrast, we found increased levels of phospho-PTEN (inactive) in embryonic and injured arterial tissues (immunohistochemistry showed phospho-PTEN predominantly localized to the growing neointima) compared with adult aortic and sham-injured carotid artery tissues (Figure 4), consistent with increased growth rates.
|
To determine whether PTEN inactivity is associated with serum-independent SMC growth, embryonic, neointimal, and adult SMCs were maintained under serum-free conditions for 72 hours and then analyzed by Western blot analysis for total PTEN versus phospho-PTEN. In agreement with our previous work,3 total PTEN protein was expressed at similar levels by all SMC cultures. In contrast, increased levels of phospho-PTEN were observed in serum-deprived but growing embryonic and neointimal SMCs compared with serum-deprived, growth-arrested adult SMCs (Figure 5A), consistent with constitutive activity of Akt-mediated signaling and high growth rates of embryonic and neointimal SMCs under serum-free conditions. We next examined whether loss of endogenous PTEN induces a serum-independent phenotype in adult SMCs by treating adult SMCs with PTEN-specific antisense morpholino oligonucleotides and analyzing their ability to replicate DNA under serum-deprived and serum-stimulated conditions. Western blot analysis showed endogenous PTEN levels were reduced significantly by antisense treatment (Figure 5B). Control (untreated) and inverse antisense-treated SMCs exhibited low replication rates under serum-deprived conditions but increased rates in response to serum stimulation (Figure 5C). In contrast, antisense-treated SMCs exhibited high rates of growth under serum-free conditions, with replication rates that approached those observed in serum-stimulated control SMCs (Figure 5C). Serum-stimulated growth of antisense-treated SMCs was also significantly higher than control SMCs. Collectively, these data suggest PTEN is a potent endogenous inhibitor of SMC serum-independent proliferation.
|
|
Discussion |
|---|
|
TopAbstractIntroductionResultsDiscussionReferences |
|---|
At distinct times during development and after vascular injury, rat vascular SMCs undergo periods of rapid but transient proliferation and, in culture, exhibit high rates of replication under serum-deprived conditions.1,3 Embryonic and neointimal SMC serum-independent growth is independent of secreted growth factors known to stimulate growth of traditional adult-derived SMCs, such as platelet-derived growth factor or basic fibroblast growth factor, but rather is dependent on an intrinsically controlled mechanism.1,3 Likewise, control of SMC replication during intimal thickening has been shown to be independent of such growth factors,16,17 which suggests that SMCs that exhibit a unique growth phenotype distinct from traditional vascular SMCs preferentially contribute to vascular lesion formation. We report high SMC growth rates observed in embryonic and postinjury vessels are associated with increased Akt-mediated signaling and decreased PTEN activity. Serum-deprived but proliferating embryonic and neointimal SMCs exhibit constitutively activated Akt, mTOR, and p70S6K and increased expression of S6RP, consistent with increased cell cycle progression. Selective inhibition of this pathway by both pharmacological and molecular approaches blocks serum-independent SMC growth. Finally, loss of serum-independent growth potential, as observed in SMCs cultured from mature, uninjured vessels, occurs, at least in part, through the developmentally timed increase in PTEN activity.
The findings of the present study show rapid and serum-independent growth of embryonic and neointimal SMCs is dependent on constitutive activity of the translational machinery, and these findings are consistent with neointimal cells expressing a highly proliferative phenotype characteristic of embryonic SMCs rather than traditional adult-derived vascular SMCs. Others have noted transient increases in Akt, mTOR, and p70S6K activities correlating to rapid SMC replication in various vascular injury models.8,18 Because expression of this phenotype only occurs at very distinct times, it is likely that SMCs execute a cellular program in response to appropriate environmental cues, which results in the transient expression of a highly proliferative phenotype characterized by increased PI3K/Akt-mediated signaling. In culture, this would manifest as a stable cellular program characterized by the ability of these cells to replicate under serum-independent conditions. Therefore, we can speculate there is an underlying positive regulator controlling constitutive activity of the PI3K/Akt pathway to drive serum-independent growth, although we have yet to define this factor.
In addition, or alternatively as we previously speculated, the ability of SMCs to replicate under unstimulated conditions could occur through loss or inactivation of previously unidentified negative growth regulators. In the present report, we show the timed acquisition of PTEN actively represses SMC serum-independent growth. Elevated levels of phosphatidylinositol 3,4,5-trisphosphate, the predominant PTEN substrate, are observed in PTEN-deficient cells and are sufficient to activate Akt to transduce proliferative signals in the absence of other stimuli.9–11 In our system, the ability of SMCs to replicate under unstimulated conditions via inactivation of PTEN could occur through gain of upstream negative regulators or through loss of upstream positive regulators of PTEN. Therefore, identification of modulators of PTEN activity will significantly advance our knowledge of the vascular developmental process and the SMC response to injury.
PTEN, first discovered as a potent tumor suppressor, is a dual-specificity lipid and protein phosphatase.9–12 As a direct negative regulator of PI3K/Akt- and FAK-mediated signaling, PTEN promotes cell cycle arrest, apoptosis, and decreased cell migration. Studies have shown PTEN inactivation results in early embryonic lethality and altered differentiation and organization of all 3 germ layers.19,20 The present data suggest PTEN is less active in developing SMCs, thus contributing to a highly proliferative phenotype. At distinct times during the developmental process, an upregulation of PTEN activity contributes to the loss of constitutive Akt signaling and SMC quiescence. However, vascular injury results in PTEN inactivation, constitutive Akt signaling, and the reexpression of a serum-independent growth phenotype. Figure 6 summarizes our proposed role of PTEN in the control of SMC serum-independent growth. Ongoing studies in our laboratory are addressing other issues, for instance, upstream regulators, associated with PTEN function.
|
Neointimal proliferation contributing to restenosis after balloon angioplasty and stent placement continues to be the most important limitation to the success of such vascular interventions, with the overall rate of restenosis remaining relatively high (>30%).21–23 Most approaches to limit the rate of restenosis, designed to target factors that stimulate growth of traditional adult-derived serum-dependent SMCs,16,17,21 have been largely unsuccessful. Recently, an increasing number of animal and human studies have shown significant reductions in intimal thickening associated with attenuated PI3K/Akt/mTOR/p70S6K signaling after rapamycin treatment.21–28 Two-year follow-up studies in humans have shown persistent inhibition of in-stent restenosis with few, if any, adverse effects, which demonstrates the effectiveness and safety of rapamycin.27,28 Our studies show the high proliferative capability, even under serum-deprived conditions, exhibited by both embryonic and neointimal SMCs is dependent on low PTEN activity resulting in constitutive Akt-dependent signaling. Loss of this phenotype is associated with increased PTEN activity and regulated, rather than constitutive, activity of Akt-mediated signaling. Pharmacological inhibition of serum-independent growth by PI3K and/or mTOR inhibitors essentially mimics the endogenous effects of PTEN. Therefore, given the recent success of rapamycin on in-stent restenosis combined with the present data (in particular, the rapamycin data), we propose the efficacy of rapamycin in inhibiting in-stent restenosis is the result of selective growth inhibition of cells that exhibit this unique growth phenotype.
It is currently unclear whether all SMCs in the vasculature are capable of reexpressing a highly proliferative, embryonic growth phenotype after vascular injury. It was originally thought new proliferative SMCs were derived solely from preexisting medial SMCs that had dedifferentiated to a relatively immature, embryonic-like phenotype. More recently, studies have shown cells that compose the neointima arise not only from medial SMCs but also from resident adventitial cells and circulating and/or bone marrow–derived precursor cells.29–33 Regardless of origin, a number of studies provide evidence that cells responding to injury undergo a developmental sequence of events during the injury-repair process.4,34–36 Our studies demonstrate the capacity of SMCs to transiently reexpress a serum-independent growth phenotype after injury that is associated with constitutive Akt/mTOR/p70S6K activities mediated via PTEN inactivation. Therefore, selectively targeting of PTEN and/or elucidation of upstream modulators of PTEN activity might hold promise for the development of antirestenotic and antiatherosclerotic therapies.
|
Acknowledgments |
|---|
This work was supported by grants 1 RO1 HL63946-01A1 (Dr Weiser-Evans) and HL57144/HL14985 (Dr Stenmark) from the National Heart, Lung, and Blood Institute and Grant-in-Aid 9950407N from the American Heart Association (Dr Weiser-Evans).
|
Footnotes |
|---|
An online-only Data Supplement is available at http://www.circulation.org.
|
References |
|---|
|
TopAbstractIntroductionResultsDiscussionReferences |
|---|
1. Cook CL, Weiser MC, Schwartz PE, et al. Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res. 1994; 74: 189–196.
2. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983; 49: 327–333.[Medline] [Order article via Infotrieve]
3. Weiser-Evans MCM, Quinn BE, Burkard MR, et al. Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery SMC following vascular injury. J Cell Physiol. 2000; 182: 12–23.[CrossRef][Medline] [Order article via Infotrieve]
4. Weiser-Evans MCM, Schwartz PE, Grieshaber NA, et al. Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res. 2000; 87: 608–615.
5. Ferrari S, Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit Rev Biochem Mol Biol. 1994; 29: 385–413.[Medline] [Order article via Infotrieve]
6. Pearson RB, Thomas G. Regulation of p70S6K/p85S6K and its role in the cell cycle. Prog Cell Cycle Res. 1995; 1: 21–32.[Medline] [Order article via Infotrieve]
7. Thomas G, Hall MN. Tor signaling and control of cell growth. Curr Opin Cell Biol. 1997; 9: 782–787.[CrossRef][Medline] [Order article via Infotrieve]
8. Braun-Dullaeus R, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001; 21: 1152–1158.
9. Dahia PLM. PTEN, a unique tumor suppressor gene. Endocrine-Related Cancer. 2000; 7: 115–129.[Abstract]
10. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001; 114: 2375–2382.
11. Leslie NR, Downes CP. PTEN: the downside of PI3-kinase signaling. Cell Signal. 2002; 14: 285–295.[CrossRef][Medline] [Order article via Infotrieve]
12. Tsugawa K, Jones MK, Sugimachi K, et al. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci. 2002; 7: e245–e251.[Medline] [Order article via Infotrieve]
13. Vazque F, Ramaswamy S, Nakamura N, et al. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000; 20: 5010–5018.
14. Vazquez F, Grossman S, Takahashi Y, et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001; 276: 48627–48630.
15. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol. 2002; 22: 745–751.
16. Ferns GA, Raines EW, Sprugel KH, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991; 253: 1129–1132.
17. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991; 88: 3739–3743.
18. Shigematsu K, Koyama H, Olson NE, et al. Phosphatidylinositol 3-kinase signaling is important for smooth muscle cell replication after arterial injury. Arterioscler Thromb Vasc Biol. 2000; 20: 2373–2378.
19. DiCristofano A, Pesce B, Cordon-Cardo C, et al. PTEN is essential for embryonic development and tumor suppression. Nat Genet. 1998; 19: 348–355.[CrossRef][Medline] [Order article via Infotrieve]
20. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998; 8: 1169–1178.[CrossRef][Medline] [Order article via Infotrieve]
21. Marx SO, Marks AR. The development of rapamycin and its application to stent restenosis. Circulation. 2001; 104: 852–855.
22. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation. 2002; 106: 2734–2740.
23. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation. 2002; 106: 2859–2866.
24. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999; 99: 2164–2170.
25. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002; 106: 2379–2384.
26. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003; 361: 247–249.[CrossRef][Medline] [Order article via Infotrieve]
27. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2002; 106: 1610–1613.
28. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation. 2003; 107: 381–383.
29. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403–409.[CrossRef][Medline] [Order article via Infotrieve]
30. Hirschii KK, Goodell MA. Hematopoietic, vascular, and cardiac fates of bone marrow-derived stem cells. Gene Therapy. 2002; 9: 648–652.[CrossRef][Medline] [Order article via Infotrieve]
31. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone marrow cells are a source of donor intimal smooth muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001; 7: 738–741.[CrossRef][Medline] [Order article via Infotrieve]
32. Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001; 166: 7556–7562.
33. Shi Y, O’Brien JE, Fard A, et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996; 94: 1655–1664.
34. Majesky MW, Giachelli CM, Reidy MA, et al. Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ Res. 1992; 71: 759–768.
35. Kim DK, Zhang L, Dzau VJ, et al. H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury. J Clin Invest. 1994; 93: 355–360.[Medline] [Order article via Infotrieve]
36. Kowal RC, Richardson JA, Miano JM, et al. EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature. Circ Res. 1999; 84: 1166–1176.
This article has been cited by other articles:
 |
|
 |
|
  K. Selvendiran, M. L. Kuppusamy, A. Bratasz, L. Tong, B. K. Rivera, C. Rink, C. K. Sen, T. Kalai, K. Hideg, and P. Kuppusamy Inhibition of Vascular Smooth-Muscle Cell Proliferation and Arterial Restenosis by HO-3867, a Novel Synthetic Curcuminoid, through Up-Regulation of PTEN Expression J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Morello, A. Perino, and E. Hirsch Phosphoinositide 3-kinase signalling in the vascular system Cardiovasc Res, May 1, 2009; 82(2): 261 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Semsroth, R. G. Stigler, O. Y. Bernecker, E. Ruttmann-Ulmer, J. Troppmair, K. Macfelda, J. O. Bonatti, and G. Laufer Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Lasater, W. K. Bessler, L. E. Mead, W. E. Horn, D. W. Clapp, S. J. Conway, D. A. Ingram, and F. Li Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway Hum. Mol. Genet., August 1, 2008; 17(15): 2336 - 2344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Nemenoff, P. A. Simpson, S. B. Furgeson, N. Kaplan-Albuquerque, J. Crossno, P. J. Garl, J. Cooper, and M. C.M. Weiser-Evans Targeted Deletion of PTEN in Smooth Muscle Cells Results in Vascular Remodeling and Recruitment of Progenitor Cells Through Induction of Stromal Cell-Derived Factor-1{alpha} Circ. Res., May 9, 2008; 102(9): 1036 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, Y. Bai, L. Qin, P. Zhang, T. Yi, S. A. Teesdale, L. Zhao, J. S. Pober, and G. Tellides Interferon-{gamma} Induces Human Vascular Smooth Muscle Cell Proliferation and Intimal Expansion by Phosphatidylinositol 3-Kinase Dependent Mammalian Target of Rapamycin Raptor Complex 1 Activation Circ. Res., September 14, 2007; 101(6): 560 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Rice, D. H. Desai, D. L. Preston, P. S. Wehner, and E. R. Blough Vascular: Uniaxial stretch-induced regulation of mitogen-activated protein kinase, Akt and p70 S6 kinase in the ageing Fischer 344 x Brown Norway rat aorta Exp Physiol, September 1, 2007; 92(5): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Li, A. M. Munchhof, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F.-C. Yang, et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells Hum. Mol. Genet., June 1, 2006; 15(11): 1921 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Munchhof, F. Li, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, X. Li, J. Yuan, F.-C. Yang, and D. A. Ingram Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells Hum. Mol. Genet., June 1, 2006; 15(11): 1858 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miano Fishing for Function in Zebrafish Circ. Res., March 31, 2006; 98(6): 723 - 726. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wenzlau, P. J. Garl, P. Simpson, K. R. Stenmark, J. West, K. B. Artinger, R. A. Nemenoff, and M. C.M. Weiser-Evans Embryonic Growth-Associated Protein Is One Subunit of a Novel N-Terminal Acetyltransferase Complex Essential for Embryonic Vascular Development Circ. Res., March 31, 2006; 98(6): 846 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Breemen, D. Poburko, and E. B. Okon TRP Proteins: A New Dimension in the Treatment of Occlusive Vascular Disease Circ. Res., March 3, 2006; 98(4): 446 - 447. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Li, C. Zhang, S. Schaefer, A. Estes, and K. U. Malik ANG II-induced neointimal growth is mediated via cPLA2- and PLD2-activated Akt in balloon-injured rat carotid artery Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2592 - H2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kaplan-Albuquerque, Y. E. Bogaert, V. Van Putten, M. C. Weiser-Evans, and R. A. Nemenoff Patterns of Gene Expression Differentially Regulated by Platelet-derived Growth Factor and Hypertrophic Stimuli in Vascular Smooth Muscle Cells: MARKERS FOR PHENOTYPIC MODULATION AND RESPONSE TO INJURY J. Biol. Chem., May 20, 2005; 280(20): 19966 - 19976. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||